{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:09:24Z","timestamp":1763705364517,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T00:00:00Z","timestamp":1507593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Helsinki University Central Hospital Research Fund"},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Finnish Cancer Society"},{"DOI":"10.13039\/501100005878","name":"Terveyden Tutkimuksen Toimikunta","doi-asserted-by":"publisher","award":["266528"],"award-info":[{"award-number":["266528"]}],"id":[{"id":"10.13039\/501100005878","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s10689-017-0046-2","type":"journal-article","created":{"date-parts":[[2017,10,9]],"date-time":"2017-10-09T23:32:12Z","timestamp":1507591932000},"page":"321-331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy"],"prefix":"10.1007","volume":"17","author":[{"given":"Rainer","family":"Fagerholm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Faltinova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsi","family":"Aaltonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristiina","family":"Aittom\u00e4ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e4ivi","family":"Heikkil\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervi","family":"Halttunen-Nieminen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0916-2976","authenticated-orcid":false,"given":"Heli","family":"Nevanlinna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Blomqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,10]]},"reference":[{"key":"46_CR1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3109\/02841861003782017","volume":"49","author":"G Engholm","year":"2010","unstructured":"Engholm G, Ferlay J, Christensen N et al (2010) NORDCAN\u2013a Nordic tool for cancer information, planning, quality control and research. Acta Oncol 49:725\u2013736","journal-title":"Acta Oncol"},{"key":"46_CR2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamaoncol.2016.1025","volume":"2","author":"P Maas","year":"2016","unstructured":"Maas P, Barrdahl M, Joshi AD et al (2016) breast cancer risk from modifiable and nonmodifiable risk factors among White Women in the United States. JAMA Oncol 2:1295\u20131302","journal-title":"JAMA Oncol"},{"key":"46_CR3","first-page":"982","volume":"92","author":"GA Greendale","year":"1998","unstructured":"Greendale GA, Reboussin BA, Hogan P et al (1998) Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen\/Progestin Interventions Trial. Obstet Gynecol 92:982\u2013988","journal-title":"Obstet Gynecol"},{"key":"46_CR4","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","volume":"350","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"1997","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350:1047\u20131059","journal-title":"Lancet"},{"key":"46_CR5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1054\/bjoc.2001.1899","volume":"85","author":"H Olsson","year":"2001","unstructured":"Olsson H, Bladstrom A, Ingvar C et al (2001) A population-based cohort study of HRT use and breast cancer in southern Sweden. Br J Cancer 85:674\u2013677","journal-title":"Br J Cancer"},{"key":"46_CR6","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/jama.2010.1500","volume":"304","author":"RT Chlebowski","year":"2010","unstructured":"Chlebowski RT, Anderson GL, Gass M et al (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684\u20131692","journal-title":"JAMA"},{"key":"46_CR7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/jamaoncol.2015.0494","volume":"1","author":"RT Chlebowski","year":"2015","unstructured":"Chlebowski RT, Rohan TE, Manson JE et al (2015) Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women\u2019s Health Initiative Randomized Clinical Trials. JAMA Oncol 1:296\u2013305","journal-title":"JAMA Oncol"},{"key":"46_CR8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","volume":"310","author":"JE Manson","year":"2013","unstructured":"Manson JE, Chlebowski RT, Stefanick ML et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials. JAMA 310:1353\u20131368","journal-title":"JAMA"},{"key":"46_CR9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ejso.2005.02.005","volume":"31","author":"N Biglia","year":"2005","unstructured":"Biglia N, Sgro L, Defabiani E et al (2005) The influence of hormone replacement therapy on the pathology of breast cancer. Eur J Surg Oncol 31:467\u2013472","journal-title":"Eur J Surg Oncol"},{"key":"46_CR10","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/(SICI)1097-0215(199806)79:3<278::AID-IJC12>3.0.CO;2-5","volume":"79","author":"P Bonnier","year":"1998","unstructured":"Bonnier P, Bessenay F, Sasco AJ et al (1998) Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer 79:278\u2013282","journal-title":"Int J Cancer"},{"key":"46_CR11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/archsurg.137.9.1015","volume":"137","author":"J Cheek","year":"2002","unstructured":"Cheek J, Lacy J, Toth-Fejel S et al (2002) The impact of hormone replacement therapy on the detection and stage of breast cancer. Arch Surg 137:1015\u20131019","journal-title":"Arch Surg"},{"key":"46_CR12","first-page":"1175","volume":"12","author":"JR Daling","year":"2003","unstructured":"Daling JR, Malone KE, Doody DR et al (2003) Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50\u201364 years. Cancer Epidemiol Biomarkers Prev 12:1175\u20131181","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"46_CR13","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.1998.16.9.3115","volume":"16","author":"K Holli","year":"1998","unstructured":"Holli K, Isola J, Cuzick J (1998) Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 16:3115\u20133120","journal-title":"J Clin Oncol"},{"key":"46_CR14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF01806152","volume":"38","author":"C Magnusson","year":"1996","unstructured":"Magnusson C, Holmberg L, Norden T et al (1996) Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 38:325\u2013334","journal-title":"Breast Cancer Res Treat"},{"key":"46_CR15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/jcp.51.12.935","volume":"51","author":"IF O\u2019Connor","year":"1998","unstructured":"O\u2019Connor IF, Shembekar MV, Shousha S (1998) Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. J Clin Pathol 51:935\u2013938","journal-title":"J Clin Pathol"},{"key":"46_CR16","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/bcr2145","volume":"10","author":"LU Rosenberg","year":"2008","unstructured":"Rosenberg LU, Granath F, Dickman PW et al (2008) Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res 10:R78","journal-title":"Breast Cancer Res"},{"key":"46_CR17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF02573064","volume":"9","author":"V Sacchini","year":"2002","unstructured":"Sacchini V, Zurrida S, Andreoni G et al (2002) Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Ann Surg Oncol 9:266\u2013271","journal-title":"Ann Surg Oncol"},{"key":"46_CR18","doi-asserted-by":"crossref","first-page":"342e1","DOI":"10.1016\/j.ajog.2006.10.901","volume":"196","author":"F Schuetz","year":"2007","unstructured":"Schuetz F, Diel IJ, Pueschel M et al (2007) Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol 196:342e1\u2013342e9","journal-title":"Am J Obstet Gynecol"},{"key":"46_CR19","first-page":"167","volume":"178","author":"R Squitieri","year":"1994","unstructured":"Squitieri R, Tartter PI, Ahmed S et al (1994) Carcinoma of the breast in postmenopausal hormone user and nonuser control groups. J Am Coll Surg 178:167\u2013170","journal-title":"J Am Coll Surg"},{"key":"46_CR20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/oxfordjournals.aje.a115328","volume":"130","author":"L Bergkvist","year":"1989","unstructured":"Bergkvist L, Adami HO, Persson I et al (1989) Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 130:221\u2013228","journal-title":"Am J Epidemiol"},{"key":"46_CR21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.amjsurg.2008.06.023","volume":"196","author":"D Christante","year":"2008","unstructured":"Christante D, Pommier S, Garreau J et al (2008) Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up. Am J Surg 196:505\u2013511","journal-title":"Am J Surg"},{"key":"46_CR22","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/sj.bjc.6690543","volume":"80","author":"H Jernstrom","year":"1999","unstructured":"Jernstrom H, Frenander J, Ferno M et al (1999) Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 80:1453\u20131458","journal-title":"Br J Cancer"},{"key":"46_CR23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF00051340","volume":"4","author":"J Yuen","year":"1993","unstructured":"Yuen J, Persson I, Bergkvist L et al (1993) Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for healthy drug-user effect. Cancer Causes Control 4:369\u2013374","journal-title":"Cancer Causes Control"},{"key":"46_CR24","doi-asserted-by":"crossref","first-page":"973","DOI":"10.7326\/0003-4819-127-11-199712010-00004","volume":"127","author":"TA Sellers","year":"1997","unstructured":"Sellers TA, Mink PJ, Cerhan JR et al (1997) The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 127:973\u2013980","journal-title":"Ann Intern Med"},{"key":"46_CR25","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1001\/jama.1991.03460150089030","volume":"265","author":"KK Steinberg","year":"1991","unstructured":"Steinberg KK, Thacker SB, Smith SJ et al (1991) A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265:1985\u20131990","journal-title":"JAMA"},{"key":"46_CR26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ijc.20638","volume":"113","author":"O Kilpivaara","year":"2005","unstructured":"Kilpivaara O, Bartkova J, Eerola H et al (2005) Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 113:575\u2013580","journal-title":"Int J Cancer"},{"key":"46_CR27","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/92.18.1529","volume":"92","author":"K Syrjakoski","year":"2000","unstructured":"Syrjakoski K, Vahteristo P, Eerola H et al (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92:1529\u20131531","journal-title":"J Natl Cancer Inst"},{"key":"46_CR28","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.155","volume":"40","author":"R Fagerholm","year":"2008","unstructured":"Fagerholm R, Hofstetter B, Tommiska J et al (2008) NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40:844\u2013853","journal-title":"Nat Genet"},{"key":"46_CR29","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0959-8049(00)00093-9","volume":"36","author":"H Eerola","year":"2000","unstructured":"Eerola H, Blomqvist C, Pukkala E et al (2000) Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 36:1143\u20131148","journal-title":"Eur J Cancer"},{"key":"46_CR30","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1086\/341943","volume":"71","author":"P Vahteristo","year":"2002","unstructured":"Vahteristo P, Bartkova J, Eerola H et al (2002) A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71:432\u2013438","journal-title":"Am J Hum Genet"},{"key":"46_CR31","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1054\/bjoc.2000.1626","volume":"84","author":"P Vahteristo","year":"2001","unstructured":"Vahteristo P, Eerola H, Tamminen A et al (2001) A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 84:704\u2013708","journal-title":"Br J Cancer"},{"key":"46_CR32","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1097\/01.AOG.0000241091.86268.6e","volume":"108","author":"H Lyytinen","year":"2006","unstructured":"Lyytinen H, Pukkala E, Ylikorkala O (2006) Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 108:1354\u20131360","journal-title":"Obstet Gynecol"},{"key":"46_CR33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403\u2013410","journal-title":"Histopathology"},{"key":"46_CR34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10549-008-9908-5","volume":"113","author":"K Aaltonen","year":"2009","unstructured":"Aaltonen K, Amini RM, Landberg G et al (2009) Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Res Treat 113:75\u201382","journal-title":"Breast Cancer Res Treat"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10689-017-0046-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-017-0046-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-017-0046-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T03:31:05Z","timestamp":1528860665000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10689-017-0046-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,10]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["46"],"URL":"https:\/\/doi.org\/10.1007\/s10689-017-0046-2","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"type":"print","value":"1389-9600"},{"type":"electronic","value":"1573-7292"}],"subject":[],"published":{"date-parts":[[2017,10,10]]}}}